-
Sector Analysis
NewRetinitis Pigmentosa (RP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in RP therapeutics. - More than 1,000,000 diagnosed prevalent cases of RP are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for RP. - The treatment guidelines for RP have been well established globally. Roche’s Luxturna (voretigene neparvovec) dominate the RP market. - Majority of RP pipeline assets are protein and peptide activator, followed by receptor activator. - A total of 107 clinical...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RP-2 in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RP-2 in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RP-2 in Nasopharyngeal Cancer Drug Details: RP-2 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RP-12146 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RP-12146 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RP-12146 in Breast Cancer Drug Details: RP-12146 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RP-1664 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RP-1664 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RP-1664 in Solid Tumor Drug Details: RP-1664 is under development for...
-
Product Insights
RP Global Professio Solar PV Project, Croatia
RP Global Professio Solar PV Project is proposed to be developed in Croatia. Empower your strategies with our RP Global Professio Solar PV Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RP-2 in Metastatic Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RP-2 in Metastatic Breast Cancer Drug Details: RP-2 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval Analysis for Retinal Degeneration
Overview How likely is it that the drugs in Retinal Degeneration will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Retinal Degeneration Overview Retinal degeneration refers to a group of diseases that...
-
Product Insights
RP Global Tartessos Solar PV Park
RP Global Tartessos Solar PV Park is a solar PV project located in Castile and León, Spain. The project is owned and being developed by RP Global Austria GmbH. The project is at the permitting stage. Empower your strategies with our RP Global Tartessos Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brilaroxazine in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brilaroxazine in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brilaroxazine in Parkinson's Disease Drug Details: RP-5063 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Metastatic Melanoma Drug Details: RP-1 is under development...